Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04959474 · ClinicalTrials.gov registry record · NA
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
A NA study of Invasive Breast Carcinoma and Triple-Negative Breast Carcinoma, sponsored by Thomas Jefferson University.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT04959474 is a NA study of Invasive Breast Carcinoma and Triple-Negative Breast Carcinoma that is actively recruiting participants, run by Thomas Jefferson University. The registered enrollment target is 80 participants, below the 483-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04959474, a NA study of Invasive Breast Carcinoma and Triple-Negative Breast Carcinoma, is actively recruiting participants, sponsored by Thomas Jefferson University.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies the effect of calorie reduction while undergoing stereotactic ablative radiation therapy in treating patients with breast cancer. Stereotactic ablative radiation therapy (sABR) is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor, while limiting the dose to the surrounding organ. Giving SABR before surgery may make the tumor smaller. Adding dietary restrictions in combination with radiation therapy may help increase local control and decrease the spread of the cancer to other places in the body. The purpose of this trial is to identify if there is a decrease in tumor tissue in patients undergoing caloric restriction during pre-operative SABR, compared to patients undergoing pre-operative SABR alone.
Conditions Studied
Interventions
- RADIATION Stereotactic Body Radiation Therapy
- OTHER Best Practice
- OTHER Dietary Intervention
- PROCEDURE Resection
- PROCEDURE Sentinel Lymph Node Biopsy
Study Locations (1)
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-08-23 |
| Est. Completion | 2028-11-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04959474
The ClinicalTrials.gov registry entry for NCT04959474 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (83% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Invasive Breast Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Stereotactic Body Radiation Therapy is the first listed.
NCT04959474 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04959474 about?
NCT04959474 is a clinical study titled "Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer". This phase II trial studies the effect of calorie reduction while undergoing stereotactic ablative radiation therapy in treating patients with breast cancer. Stereotactic ablative radiation therapy (sABR) is a highly focused radiation treatment that gives an intense dose of radiation concentrated on...
What is the current status of trial NCT04959474?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2021-08-23. Estimated completion is 2028-11-01.
What conditions does trial NCT04959474 study?
This clinical trial studies the following conditions: Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma, Breast Ductal Carcinoma In Situ, Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8.
What interventions are being tested in trial NCT04959474?
The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION), Best Practice (OTHER), Dietary Intervention (OTHER), Resection (PROCEDURE), Sentinel Lymph Node Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT04959474?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04959474 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
RECRUITING · NA
-
Neoadjuvant Breast Cancer Time Restricted Eating
RECRUITING · NA
-
NearWave Optical Molecular Monitoring
RECRUITING · NA
-
Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer
ACTIVE NOT RECRUITING · NA
-
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
ACTIVE NOT RECRUITING · NA
-
Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Invasive Breast Carcinoma
All registered trials for this condition
Triple-Negative Breast Carcinoma
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.